Page last updated: 2024-12-11
pr-104a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
PR-104A: 3,5-dinitrobenzamide nitrogen mustard, an alkyating antineoplastic; PR-104A is the corresponding alcohol of PR104 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9848786 |
CHEMBL ID | 4438907 |
SCHEMBL ID | 366334 |
MeSH ID | M0515481 |
Synonyms (23)
Synonym |
---|
680199-06-8 |
pr-104a |
SCHEMBL366334 |
AZICEEZSDKZDHX-UHFFFAOYSA-N |
2-((2-bromoethyl)-2-{[(2-hydroxyethyl)amino]carbonyl}-4,6-dinitroanilino)ethyl methanesulfonate |
AKOS025147034 |
397986RF9L , |
3,5-dinitrobenzamide nitrogen mustard |
2-(n-(2-bromoethyl)-2-(((2-hydroxyethyl)amino)carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate |
benzamide, 2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-n-(2-hydroxyethyl)-3,5-dinitro- |
2-((2-bromoethyl)(2-((methylsulfonyl)oxy)ethyl)amino)-n-(2-hydroxyethyl)-3,5-dinitrobenzamide |
2-((2-bromoethyl)(2-((2-hydroxyethyl)carbamoyl)-4,6-dinitrophenyl)amino)ethyl methanesulfonate |
J-505203 |
2-[n-(2-bromoethyl)-2-(2-hydroxyethylcarbamoyl)-4,6-dinitroanilino]ethyl methanesulfonate |
pr 104a |
unii-397986rf9l |
sn 27858 |
MS-29270 |
CHEMBL4438907 |
HY-14572 |
CS-0003452 |
2-((2-bromoethyl)(2-((2-hydroxyethyl)carbamoyl)-4,6-dinitrophenyl)amino)ethylmethanesulfonate |
AKOS040749231 |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" Here, we report a population pharmacokinetic (PK) model for PR-104 and PR-104A in non-human species and in humans." | ( A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. Choy, SS; Hicks, KO; Holford, NH; Melink, TJ; Patel, K; Wilson, WR, 2011) | 0.84 |
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
"The purpose of this phase Ib clinical trial was to determine the maximum tolerated dose (MTD) of PR-104 a bioreductive pre-prodrug given in combination with gemcitabine or docetaxel in patients with advanced solid tumours." | ( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012) | 0.38 |
"PR-104 was administered as a one-hour intravenous infusion combined with docetaxel 60 to 75 mg/m2 on day one given with or without granulocyte colony stimulating factor (G-CSF) on day two or administrated with gemcitabine 800 mg/m2 on days one and eight, of a 21-day treatment cycle." | ( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012) | 0.38 |
" The MTD of PR-104 was 140 mg/m2 when combined with gemcitabine, 200 mg/m2 when combined with docetaxel 60 mg/m2, 770 mg/m2 when combined with docetaxel 60 mg/m2 plus G-CSF and ≥770 mg/m2 when combined with docetaxel 75 mg/m2 plus G-CSF." | ( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012) | 0.38 |
" A recommended dose was identified for phase II trials of PR-104 of 770 mg/m2 combined with docetaxel 60 to 75 mg/m2 both given on day one of a 21-day treatment cycle supported by prophylactic G-CSF (NCT00459836)." | ( PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR, 2012) | 0.38 |
" PR-104 monotherapy elicited significant reductions in growth of Hep3B and HepG2 xenografts, and the combination with sorafenib was significantly active in all 4 xenograft models." | ( Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. Abbattista, MR; Gu, Y; Guise, CP; Jamieson, SM; Nickel, JE; Patterson, AV; Pullen, SM; Wilson, WR, 2015) | 0.42 |
Dosage Studied
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Other Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (1)
Process | via Protein(s) | Taxonomy |
---|---|---|
2,4,6-trinitrotoluene catabolic process | Oxygen-insensitive NAD(P)H nitroreductase | Escherichia coli K-12 |
2,4,6-trinitrotoluene catabolic process | Oxygen-insensitive NAD(P)H nitroreductase | Escherichia coli K-12 |
[Information is prepared from geneontology information from the June-17-2024 release] |
Molecular Functions (7)
Process | via Protein(s) | Taxonomy |
---|---|---|
NAD(P)H dehydrogenase (quinone) activity | Oxygen-insensitive NAD(P)H nitroreductase | Escherichia coli K-12 |
6,7-dihydropteridine reductase activity | Oxygen-insensitive NAD(P)H nitroreductase | Escherichia coli K-12 |
FMN binding | Oxygen-insensitive NAD(P)H nitroreductase | Escherichia coli K-12 |
oxidoreductase activity | Oxygen-insensitive NAD(P)H nitroreductase | Escherichia coli K-12 |
identical protein binding | Oxygen-insensitive NAD(P)H nitroreductase | Escherichia coli K-12 |
protein homodimerization activity | Oxygen-insensitive NAD(P)H nitroreductase | Escherichia coli K-12 |
oxidoreductase activity, acting on other nitrogenous compounds as donors, with NAD or NADP as acceptor | Oxygen-insensitive NAD(P)H nitroreductase | Escherichia coli K-12 |
[Information is prepared from geneontology information from the June-17-2024 release] |
Ceullar Components (2)
Process | via Protein(s) | Taxonomy |
---|---|---|
cytosol | Oxygen-insensitive NAD(P)H nitroreductase | Escherichia coli K-12 |
membrane | Oxygen-insensitive NAD(P)H nitroreductase | Escherichia coli K-12 |
cytosol | Oxygen-insensitive NAD(P)H nitroreductase | Escherichia coli K-12 |
[Information is prepared from geneontology information from the June-17-2024 release] |
Bioassays (20)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1683168 | Selectivity index, ratio of IC50 for human DU145 cells under normoxic condition to IC50 human PC-3 cells under hypoxia condition incubated for 2 hrs followed by washed with fresh media incubated for 3 days by alamar blue assay | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31 | Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer. |
AID1683173 | Lipophilicity, logD of compound at pH 7.4 by microscale shake flask method | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31 | Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer. |
AID1683169 | Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 2 hrs under hypoxic condition followed washed with fresh media incubated for 3 days by alamar blue assay | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31 | Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer. |
AID1683170 | Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 2 hrs under normoxic condition followed by washed with fresh media incubated for 3 days by alamar blue assay | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31 | Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer. |
AID1581891 | Substrate activity at Escherichia coli nitroreductase nfsB assessed as ratio of Kcat/Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method based Michaelis-Menten plot analysis relative to CB1954/NfsB | 2020 | European journal of medicinal chemistry, Feb-01, Volume: 187 | Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer. |
AID1683172 | Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 2 hrs under hypoxic condition followed by washed with fresh media incubated for 3 days by alamar blue assay | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31 | Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer. |
AID1581890 | Substrate activity at Escherichia coli nitroreductase nfsA assessed as ratio of Kcat/Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method based Michaelis-Menten plot analysis relative to CB1954/NfsB | 2020 | European journal of medicinal chemistry, Feb-01, Volume: 187 | Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer. |
AID1683167 | Selectivity index, ratio of IC50 for human PC-3 cells under normoxic condition to IC50 human PC-3 cells under hypoxia condition incubated for 2 hrs followed by washed with fresh media incubated for 3 days by alamar blue assay | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31 | Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer. |
AID1595314 | Substrate activity at Escherichia coli nitroreductase nfsB assessed as Kcat using NADH as cofactor at 0 to 800 mM in Tris-Cl buffer at pH 7.5 by spectrophotometric method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells. |
AID1683166 | Cytotoxicity against human PC-3 cells assessed as reduction in cell viability preincubated for 4 hrs in hypoxia and further incubated for 5 days in fresh medium by SRB assay | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31 | Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer. |
AID1683171 | Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 2 hrs under normoxic condition followed by washed with fresh media incubated for 3 days by alamar blue assay | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31 | Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer. |
AID1595320 | Substrate activity at Escherichia coli nitroreductase nfsB assessed as ratio of Kcat/Km up to 80 mM using NADH as cofactor relative to CB1954/NfsB | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells. |
AID1581877 | Substrate activity at Escherichia coli nitroreductase nfsB assessed as Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method based Michaelis-Menten plot analysis | 2020 | European journal of medicinal chemistry, Feb-01, Volume: 187 | Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer. |
AID1581869 | Substrate activity at Escherichia coli nitroreductase nfsA assessed as Kcat using NADPH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method | 2020 | European journal of medicinal chemistry, Feb-01, Volume: 187 | Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer. |
AID1581883 | Substrate activity at Escherichia coli nitroreductase nfsA assessed as ratio of Kcat/Km using NADPH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometry based Michaelis-Menten plot analysis | 2020 | European journal of medicinal chemistry, Feb-01, Volume: 187 | Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer. |
AID1581876 | Substrate activity at Escherichia coli nitroreductase nfsA assessed as Km using NADPH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometry based Michaelis-Menten plot analysis | 2020 | European journal of medicinal chemistry, Feb-01, Volume: 187 | Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer. |
AID1595316 | Substrate activity at Escherichia coli nitroreductase nfsB assessed as ratio of Kcat/Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells. |
AID1581870 | Substrate activity at Escherichia coli nitroreductase nfsB assessed as Kcat using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method | 2020 | European journal of medicinal chemistry, Feb-01, Volume: 187 | Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer. |
AID1581884 | Substrate activity at Escherichia coli nitroreductase nfsB assessed as ratio of Kcat/Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method based Michaelis-Menten plot analysis | 2020 | European journal of medicinal chemistry, Feb-01, Volume: 187 | Prodrugs for nitroreductase-based cancer therapy-3: Antitumor activity of the novel dinitroaniline prodrugs/Ssap-NtrB enzyme suicide gene system: Synthesis, in vitro and in silico evaluation in prostate cancer. |
AID1595315 | Substrate activity at Escherichia coli nitroreductase nfsB assessed as Km using NADH as cofactor in Tris-Cl buffer at pH 7.5 by spectrophotometric method | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (25)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (16.00) | 29.6817 |
2010's | 18 (72.00) | 24.3611 |
2020's | 3 (12.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.59
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.59) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 2 (8.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 23 (92.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |